Trial
NCT04577820
Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)
Phase IIIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Regeneron Pharmaceuticals
Collaborators
—
Condition
Fibrodyplasia Ossificans Progressiva (FOP)
Intervention
garetosmab
Why stopped
Phase 2 Study R2477-FOP-1940 has been withdrawn and the next phase of the development program is being planned
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-11-01